ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2318

Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice

Christina Charles-Schoeman1, Jennifer Wang 2, Ani Shahbazian 2, Jeremy Papesh 2 and Srinivasa Reddy 2, 1University of California, Los Angeles, CA, 2UCLA Medical Center, Los Angeles

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: arteriosclerosis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster III: Comorbidities

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Paraoxonase 1 (PON1) is a high density lipoprotein (HDL)-associated enzyme, which promotes the anti-oxidant and anti-inflammatory properties of HDL. We previously associated low PON1 activity with increased atherosclerotic risk in patients with rheumatoid arthritis (RA). The current work investigates the relationship of PON1 activity to a lipidomics panel of pro-inflammatory bioactive lipid mediators (BLM) in patients with RA and arthritic K/BxN mice.

Methods: Group A included 16 RA patients with carotid atherosclerosis (RA-ATH), 16 RA patients without carotid ATH (RA), and 16 healthy controls (HC). Group B included 29 arthritic K/BxN mice, (9 weeks (n=10), 14 weeks (n=12), 21 weeks (n=7)), and 21 non-arthritic control mice, (14 weeks, KRN (n=10), Ag7 (n= 11)). Circulating PON1 activity was measured using 3 different substrates: phenylacetate (arylesterase assay), dihydrocoumarin (lactonase assay), and paraoxon (paraoxonase assay). Liquid chromatography–electrospray ionization, tandem mass spectroscopy was performed for a panel of 10 circulating BLM including TXB2, 13 HODE, 9 HODE, 17S-HDHA, 15 HETE, 14 S-HDHA, 11 HETE, 12 HETE, 5 HETE, and 5-oxoETE.  

Results: PON1 activity was lower in patients with RA compared to HC and was significantly lower in the RA-ATH group compared to the RA group by both paraoxonase and lactonase assays. Similarly, PON1 activity was lower in arthritic K/BxN mice compared to KRN/Ag7 non-arthritic controls. Multiple BLMs were elevated in RA patients and K/BxN mice compared to controls, with trends for highest levels in the RA-ATH group compared to RA and HC groups (Table 1). Lower PON1 activity by arylesterase and lactonase assays correlated with higher levels of several BLMs in both humans and mice (Table 2).

Conclusion: Low circulating activity of the HDL-associated enzyme PON1 associates with higher pro-inflammatory BLMs in both RA patients and arthritic K/BxN mice. This work suggests a potential mechanism for increase atherosclerotic risk in patients with active RA via suppression of PON1 activity and elevation in pro-inflammatory lipid mediators. Further work is warranted to determine if PON1 represents a potential “dual” therapeutic target in patients with RA.


Lipidomics abstract Table 1 6-3-19.3

Values are mean ± SD. Units are ng/ml for all BLMs. *p<0.05 compared to HC or Ag7/KRN. # p<0.05 compared to RA-ATH.


Lipidomics Abstract Table 2 6-3-19.3

*p<0.05, # p ≤ 0.1 for Spearman correlation coefficient.


Disclosure: C. Charles-Schoeman, Abbvie, 2, AbbVie, 2, Amgen, 5, BMS, 2, Bristol Myers Squibb, 2, Gilead, 5, Octapharma, 2, 5, Pfizer, 2, 5, Regeneron, 5, Regeneron/Sanofi, 5, Sanofi, 5; J. Wang, None; A. Shahbazian, None; J. Papesh, None; S. Reddy, None.

To cite this abstract in AMA style:

Charles-Schoeman C, Wang J, Shahbazian A, Papesh J, Reddy S. Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/elevated-pro-inflammatory-lipid-mediators-associate-with-low-paraoxonase-1-activity-in-patients-with-rheumatoid-arthritis-and-arthritic-k-bxn-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-pro-inflammatory-lipid-mediators-associate-with-low-paraoxonase-1-activity-in-patients-with-rheumatoid-arthritis-and-arthritic-k-bxn-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology